Search

Your search keyword '"Waidmann, Oliver"' showing total 131 results
Start Over Author "Waidmann, Oliver" Publication Year Range Last 3 years
131 results on '"Waidmann, Oliver"'

1. Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)

Author

Modest, Dominik Paul, Heinemann, Volker, Schütt, Philipp, Angermeier, Stefan, Haberkorn, Mike, Waidmann, Oliver, Graeven, Ullrich, Wille, Kai, Kunzmann, Volker, Henze, Larissa, Constantin, Christian, de Wit, Maike, Denzlinger, Claudio, Ballhausen, Alexej, Kurreck, Annika, Jelas, Ivan, Alig, Annabel Helga Sophie, Stahler, Arndt, Stintzing, Sebastian, and Oettle, Helmut

Published
2024
Full Text
View/download PDF

2. The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects

Author

Dropmann, Anne, Alex, Sophie, Schorn, Katharina, Tong, Chenhao, Caccamo, Tiziana, Godoy, Patricio, Ilkavets, Iryna, Liebe, Roman, Gonzalez, Daniela, Hengstler, Jan G., Piiper, Albrecht, Quagliata, Luca, Matter, Matthias S., Waidmann, Oliver, Finkelmeier, Fabian, Feng, Teng, Weiss, Thomas S., Rahbari, Nuh, Birgin, Emrullah, Rasbach, Erik, Roessler, Stephanie, Breuhahn, Kai, Tóth, Marcell, Ebert, Matthias P., Dooley, Steven, Hammad, Seddik, and Meindl-Beinker, Nadja M.

Published
2024
Full Text
View/download PDF

3. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma

Author

Stern, Louisa, Schmidt, Constantin, Kocheise, Lorenz, Joerg, Vincent, Casar, Christian, Walter, Aurélie, Drenth, Joost P.H., Papp, Maria, Gatselis, Nikolaos K., Zachou, Kalliopi, Pinter, Matthias, Scheiner, Bernhard, Vogel, Arndt, Kirstein, Martha M., Finkelmeier, Fabian, Waidmann, Oliver, Weinmann, Arndt, Milkiewicz, Piotr, Thorburn, Douglas, Halliday, Neil, Lleo, Ana, Huber, Samuel, Dalekos, George N., Lohse, Ansgar W., Wege, Henning, von Felden, Johann, and Schulze, Kornelius

Published
2024
Full Text
View/download PDF

4. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial

Author

Dorman, Klara, Boeck, Stefan, Caca, Karel, Reichert, Maximilian, Ettrich, Thomas J, Oettle, Helmut, Waidmann, Oliver, Modest, Dominik P, Müller, Lothar, Michl, Patrick, Kanzler, Stephan, Pink, Daniel, Reinacher-Schick, Anke, Geißler, Michael, Pelz, Henning, Kunzmann, Volker, Held, Swantje, Schichtl, Thomas, Heinemann, Volker, and Kullmann, Frank

Published
2024
Full Text
View/download PDF

5. Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice

Author

Schmithals, Christian, Kakoschky, Bianca, Denk, Dominic, von Harten, Maike, Klug, Jan Henrik, Hintermann, Edith, Dropmann, Anne, Hamza, Eman, Jacomin, Anne Claire, Marquardt, Jens U., Zeuzem, Stefan, Schirmacher, Peter, Herrmann, Eva, Christen, Urs, Vogl, Thomas J., Waidmann, Oliver, Dooley, Steven, Finkelmeier, Fabian, and Piiper, Albrecht

Published
2024
Full Text
View/download PDF

8. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Author

Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Waidmann, Oliver, Himmelsbach, Vera, Schulze, Kornelius, von Felden, Johann, Fründt, Thorben W., Stadler, Marc, Heinzl, Harald, Shmanko, Kateryna, Spahn, Stephan, Radu, Pompilia, Siebenhüner, Alexander R., Mertens, Joachim C., Rahbari, Nuh N., Kütting, Fabian, Waldschmidt, Dirk-Thomas, Ebert, Matthias P., Teufel, Andreas, De Dosso, Sara, Pinato, David J., Pressiani, Tiziana, Meischl, Tobias, Balcar, Lorenz, Müller, Christian, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Personeni, Nicola, Rimassa, Lorenza, Bitzer, Michael, Trojan, Jörg, Weinmann, Arndt, Wege, Henning, Dufour, Jean-François, Peck-Radosavljevic, Markus, Vogel, Arndt, and Pinter, Matthias

Published
2022
Full Text
View/download PDF

11. Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial.

Author

Himmelsbach, Vera, Jeschke, Matthias, Lange, Christian M., Scheiner, Bernhard, Pinter, Matthias, Sinner, Friedrich, Venerito, Marino, Queck, Alexander, Trojan, Jörg, Waidmann, Oliver, and Finkelmeier, Fabian

Subjects
PREVENTION of surgical complications, CANCER relapse, STATISTICAL significance, PROTEIN-tyrosine kinase inhibitors, LOGISTIC regression analysis, RETROSPECTIVE studies, SORAFENIB, DESCRIPTIVE statistics, KAPLAN-Meier estimator, LOG-rank test, DRUG efficacy, RESEARCH, MEDICAL records, ACQUISITION of data, SURVIVAL analysis (Biometry), CONFIDENCE intervals, PROGRESSION-free survival, DATA analysis software, HEPATOCELLULAR carcinoma, LIVER transplantation, IMMUNOSUPPRESSION, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: Liver transplant is an approach for the curative treatment of early stage hepatocellular carcinoma and the often underlying liver cirrhosis. However, a recurrence of the cancer is to be expected in 10 to 20% of cases after liver transplantation. The treatment of recurrent hepatocellular carcinoma remains difficult, as immunotherapy is usually not recommended for systemic treatment after transplantation. Therefore, it is often necessary to resort to tyrosine kinase inhibitors in advanced stage hepatocellular carcinoma. This multicenter trial aims at assessing the effect of tyrosine kinase inhibitors and immunosuppression on the outcome of patients with recurrent hepatocellular carcinoma after liver transplantation. Introduction: The tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib represent the first-line systemic therapy of choice for patients with hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). Under sorafenib and lenvatinib, HCC patients have shown increasingly improved overall survival in clinical studies over the years. In contrast, data on overall survival for patients with HCC recurrence after LT under TKIs are scarce and limited to small retrospective series. In this retrospective, multicenter study, we investigated the efficacy of TKI therapy and the influence of immunosuppression in patients with HCC recurrence after LT. Methods: Retrospective data were collected from four transplant centers from Germany and Austria. We included patients with HCC recurrence after LT between 2007 and 2020 who were treated with a TKI. Results: In total, we analyzed data from 46 patients with HCC recurrence after LT. The most common underlying liver disease was hepatitis C, accounting for 52.2%. The median time to relapse was 11.8 months (range 0–117.7 months). The liver graft was affected in 21 patients (45.7%), and 36 patients (78.3%) had extrahepatic metastases at initial diagnosis of recurrence, with the lung being the most commonly affected (n = 25, 54.3%). Of the total, 54.3% (n = 25) of the patients were initially treated locally; 39 (85.8%) and 7 (15.2%) patients received sorafenib and lenvatinib, respectively, as first-line systemic therapy. Median overall survival of the whole cohort was 10.9 months (95% confidence interval (95% CI) 6.9–14.9 months) and median progression free survival was 5.7 months (95% CI 2.0–9.4 months) from treatment initiation. Conclusion: Since history of liver transplantation is considered a contraindication for immunotherapy, prognosis of patients with HCC recurrence after LT remains poor. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion

Author

Bitzer, Michael, additional, Groß, Sabrina, additional, Albert, Jörg, additional, Blödt, Susanne, additional, Boda-Heggemann, Judit, additional, Brunner, Thomas, additional, Caspari, Reiner, additional, De Toni, Enrico, additional, Dombrowski, Frank, additional, Evert, Matthias, additional, Follmann, Markus, additional, Freudenberger, Paul, additional, Gani, Cihan, additional, Geier, Andreas, additional, Gkika, Eleni, additional, Götz, Martin, additional, Helmberger, Thomas, additional, Hoffmann, Ralf-Thorsten, additional, Huppert, Peter, additional, Krug, David, additional, Fougère, Christian La, additional, Lang, Hauke, additional, Langer, Thomas, additional, Lenz, Philipp, additional, Lüdde, Tom, additional, Mahnken, Andreas, additional, Nadalin, Silvio, additional, Nguyen, Hoa Huu Phuc, additional, Nothacker, Monika, additional, Ockenga, Johann, additional, Oldhafer, Karl, additional, Paprottka, Philipp, additional, Pereira, Philippe, additional, Persigehl, Thorsten, additional, Plentz, Ruben, additional, Pohl, Jürgen, additional, Recken, Heinrich, additional, Reimer, Peter, additional, Riemer, Jutta, additional, Ritterbusch, Ulrike, additional, Roeb, Elke, additional, Rüssel, Jörn, additional, Schellhaas, Barbara, additional, Schirmacher, Peter, additional, Schlitt, Hans Jürgen, additional, Schmid, Irene, additional, Schuler, Andreas, additional, Seehofer, Daniel, additional, Sinn, Marianne, additional, Stengel, Andreas, additional, Steubesand, Nadine, additional, Stoll, Christoph, additional, Tannapfel, Andrea, additional, Taubert, Anne, additional, Tholen, Reina, additional, Trojan, Jörg, additional, van Thiel, Ingo, additional, Vogel, Arndt, additional, Vogl, Thomas, additional, Wacker, Frank, additional, Waidmann, Oliver, additional, Wedemeyer, Heiner, additional, Wege, Henning, additional, Wildner, Dane, additional, Wörns, Marcus-Alexander, additional, Galle, Peter, additional, and Malek, Nisar, additional

Published
2024
Full Text
View/download PDF

13. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

Author

Groß, Sabrina, additional, Bitzer, Michael, additional, Albert, Jörg, additional, Blödt, Susanne, additional, Boda-Heggemann, Judit, additional, Brunner, Thomas, additional, Caspari, Reiner, additional, De Toni, Enrico, additional, Dombrowski, Frank, additional, Evert, Matthias, additional, Follmann, Markus, additional, Freudenberger, Paul, additional, Gani, Cihan, additional, Geier, Andreas, additional, Gkika, Eleni, additional, Götz, Martin, additional, Helmberger, Thomas, additional, Hoffmann, Ralf-Thorsten, additional, Huppert, Peter, additional, Krug, David, additional, La Fougère, Christian, additional, Lang, Hauke, additional, Langer, Thomas, additional, Lenz, Philipp, additional, Lüdde, Tom, additional, Mahnken, Andreas, additional, Nadalin, Silvio, additional, Nguyen, Hoa Huu Phuc, additional, Nothacker, Monika, additional, Ockenga, Johann, additional, Oldhafer, Karl, additional, Paprottka, Philipp, additional, Pereira, Philippe, additional, Persigehl, Thorsten, additional, Plentz, Ruben, additional, Pohl, Jürgen, additional, Recken, Heinrich, additional, Reimer, Peter, additional, Riemer, Jutta, additional, Ritterbusch, Ulrike, additional, Roeb, Elke, additional, Rüssel, Jörn, additional, Schellhaas, Barbara, additional, Schirmacher, Peter, additional, Schlitt, Hans J., additional, Schmid, Irene, additional, Schuler, Andreas, additional, Seehofer, Daniel, additional, Sinn, Marianne, additional, Stengel, Andreas, additional, Steubesand, Nadine, additional, Stoll, Christoph, additional, Tannapfel, Andrea, additional, Taubert, Anne, additional, Tholen, Reina, additional, Trojan, Jörg, additional, van Thiel, Ingo, additional, Vogel, Arndt, additional, Vogl, Thomas, additional, Wacker, Frank, additional, Waidmann, Oliver, additional, Wedemeyer, Heiner, additional, Wege, Henning, additional, Wildner, Dane, additional, Wörns, Marcus-Alexander, additional, Galle, Peter, additional, and Malek, Nisar, additional

Published
2024
Full Text
View/download PDF

14. Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114).

Author

Dorman, Klara, primary, Boeck, Stefan Hubert, additional, Caca, Karel, additional, Reichert, Maximilian, additional, Ettrich, Thomas Jens, additional, Oettle, Helmut, additional, Waidmann, Oliver, additional, Modest, Dominik Paul, additional, Müller, Lothar, additional, Michl, Patrick, additional, Kanzler, Stephan, additional, Pink, Daniel, additional, Reinacher-Schick, Anke C., additional, Geißler, Michael, additional, Pelz, Henning, additional, Kunzmann, Volker, additional, Held, Swantje, additional, Schichtl, Thomas, additional, Heinemann, Volker, additional, and Kullmann, Frank, additional

Published
2024
Full Text
View/download PDF

15. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion

Author

Groß, Sabrina, additional, Bitzer, Michael, additional, Albert, Jörg, additional, Blödt, Susanne, additional, Boda-Heggemann, Judit, additional, Brunner, Thomas, additional, Caspari, Reiner, additional, De Toni, Enrico, additional, Dombrowski, Frank, additional, Evert, Matthias, additional, Follmann, Markus, additional, Freudenberger, Paul, additional, Gani, Cihan, additional, Geier, Andreas, additional, Gkika, Eleni, additional, Götz, Martin, additional, Helmberger, Thomas, additional, Hoffmann, Ralf-Thorsten, additional, Huppert, Peter, additional, Krug, David, additional, Fougère, Christian La, additional, Lang, Hauke, additional, Langer, Thomas, additional, Lenz, Philipp, additional, Lüdde, Tom, additional, Mahnken, Andreas, additional, Nadalin, Silvio, additional, Nguyen, Hoa Huu Phuc, additional, Nothacker, Monika, additional, Ockenga, Johann, additional, Oldhafer, Karl, additional, Paprottka, Philipp, additional, Pereira, Philippe, additional, Persigehl, Thorsten, additional, Plentz, Ruben, additional, Pohl, Jürgen, additional, Recken, Heinrich, additional, Reimer, Peter, additional, Riemer, Jutta, additional, Ritterbusch, Ulrike, additional, Roeb, Elke, additional, Rüssel, Jörn, additional, Schellhaas, Barbara, additional, Schirmacher, Peter, additional, Schlitt, Hans Jürgen, additional, Schmid, Irene, additional, Schuler, Andreas, additional, Seehofer, Daniel, additional, Sinn, Marianne, additional, Stengel, Andreas, additional, Steubesand, Nadine, additional, Stoll, Christoph, additional, Tannapfel, Andrea, additional, Taubert, Anne, additional, Tholen, Reina, additional, Trojan, Jörg, additional, van Thiel, Ingo, additional, Vogel, Arndt, additional, Vogl, Thomas, additional, Wacker, Frank, additional, Waidmann, Oliver, additional, Wedemeyer, Heiner, additional, Wege, Henning, additional, Wildner, Dane, additional, Wörns, Marcus-Alexander, additional, Galle, Peter, additional, and Malek, Nisar, additional

Published
2024
Full Text
View/download PDF

16. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0

Author

Bitzer, Michael, additional, Groß, Sabrina, additional, Albert, Jörg, additional, Blödt, Susanne, additional, Boda-Heggemann, Judit, additional, Brunner, Thomas, additional, Caspari, Reiner, additional, De Toni, Enrico, additional, Dombrowski, Frank, additional, Evert, Matthias, additional, Follmann, Markus, additional, Freudenberger, Paul, additional, Gani, Cihan, additional, Geier, Andreas, additional, Gkika, Eleni, additional, Götz, Martin, additional, Helmberger, Thomas, additional, Hoffmann, Ralf-Thorsten, additional, Huppert, Peter, additional, Krug, David, additional, Fougère, Christian La, additional, Lang, Hauke, additional, Langer, Thomas, additional, Lenz, Philipp, additional, Lüdde, Tom, additional, Mahnken, Andreas, additional, Nadalin, Silvio, additional, Nguyen, Hoa Huu Phuc, additional, Nothacker, Monika, additional, Ockenga, Johann, additional, Oldhafer, Karl, additional, Paprottka, Philipp, additional, Pereira, Philippe, additional, Persigehl, Thorsten, additional, Plentz, Ruben, additional, Pohl, Jürgen, additional, Recken, Heinrich, additional, Reimer, Peter, additional, Riemer, Jutta, additional, Ritterbusch, Ulrike, additional, Roeb, Elke, additional, Rüssel, Jörn, additional, Schellhaas, Barbara, additional, Schirmacher, Peter, additional, Schlitt, Hans Jürgen, additional, Schmid, Irene, additional, Schuler, Andreas, additional, Seehofer, Daniel, additional, Sinn, Marianne, additional, Stengel, Andreas, additional, Steubesand, Nadine, additional, Stoll, Christoph, additional, Tannapfel, Andrea, additional, Taubert, Anne, additional, Tholen, Reina, additional, Trojan, Jörg, additional, van Thiel, Ingo, additional, Vogel, Arndt, additional, Vogl, Thomas, additional, Wacker, Frank, additional, Waidmann, Oliver, additional, Wedemeyer, Heiner, additional, Wege, Henning, additional, Wildner, Dane, additional, Wörns, Marcus-Alexander, additional, Galle, Peter, additional, and Malek, Nisar, additional

Published
2024
Full Text
View/download PDF

17. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

19. Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians

Author

Fischer, Janett, primary, Koukoulioti, Eleni, additional, Müller, Tobias, additional, Heyne, Renate, additional, Eslam, Mohammed, additional, George, Jacob, additional, Finkelmeier, Fabian, additional, Waidmann, Oliver, additional, Berg, Thomas, additional, and van Bömmel, Florian, additional

Published
2023
Full Text
View/download PDF

20. Alternating application of gemcitabine/ nab -paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the...

Author

Dorman, Klara, Boeck, Stefan Hubert, Caca, Karel, Reichert, Maximilian, Ettrich, Thomas Jens, Oettle, Helmut, Waidmann, Oliver, Modest, Dominik Paul, Müller, Lothar, Michl, Patrick, Kanzler, Stephan, Pink, Daniel, Reinacher-Schick, Anke C., Geißler, Michael, Pelz, Henning, Kunzmann, Volker, Held, Swantje, Schichtl, Thomas, Heinemann, Volker, and Kullmann, Frank

Published
2024
Full Text
View/download PDF

21. Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile

Author

Stern, Louisa, primary, Schmidt, Constantin, additional, Casar, Christian, additional, Walter, Aurélie, additional, Drenth, J.P.H., additional, Nevens, Frederik, additional, Papp, Maria, additional, Gatselis, Nikolaos, additional, Zachou, Kalliopi, additional, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Vogel, Arndt, additional, Kirstein, Martha M, additional, Finkelmeier, Fabian, additional, Weinmann, Arndt, additional, Waidmann, Oliver, additional, Milkiewicz, Piotr, additional, Thorburn, Douglas, additional, Halliday, Neil, additional, Lleo, Ana, additional, Huber, Samuel, additional, Dalekos, George, additional, Lohse, Ansgar W., additional, Wege, Henning, additional, Nault, Jean Charles, additional, von Felden, Johann, additional, and Schulze, Kornelius, additional

Published
2023
Full Text
View/download PDF

22. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome

Author

Bitzer, Michael, additional, Groß, Sabrina, additional, Albert, Jörg, additional, Boda-Heggemann, Judit, additional, Brunner, Thomas, additional, Caspari, Reiner, additional, De Toni, Enrico, additional, Dombrowski, Frank, additional, Evert, Matthias, additional, Geier, Andreas, additional, Gkika, Eleni, additional, Götz, Martin, additional, Helmberger, Thomas, additional, Hoffmann, Ralf-Thorsten, additional, Huppert, Peter, additional, Kautz, Achim, additional, Krug, David, additional, Fougère, Christian La, additional, Lang, Hauke, additional, Lenz, Philipp, additional, Lüdde, Tom, additional, Mahnken, Andreas, additional, Nadalin, Silvio, additional, Nguyen, Hoa Huu Phuc, additional, Ockenga, Johann, additional, Oldhafer, Karl, additional, Paprottka, Philipp, additional, Pereira, Philippe, additional, Persigehl, Thorsten, additional, Plentz, Ruben, additional, Pohl, Jürgen, additional, Recken, Heinrich, additional, Reimer, Peter, additional, Riemer, Jutta, additional, Ritterbusch, Ulrike, additional, Roeb, Elke, additional, Rüssel, Jörn, additional, Schellhaas, Barbara, additional, Schirmacher, Peter, additional, Schlitt, Hans Jürgen, additional, Schmid, Irene, additional, Schuler, Andreas, additional, Seehofer, Daniel, additional, Sinn, Marianne, additional, Stengel, Andreas, additional, Stoll, Christoph, additional, Tannapfel, Andrea, additional, Taubert, Anne, additional, Tholen, Reina, additional, Trojan, Jörg, additional, van Thiel, Ingo, additional, Vogel, Arndt, additional, Vogl, Thomas, additional, Wacker, Frank, additional, Waidmann, Oliver, additional, Wedemeyer, Heiner, additional, Wege, Henning, additional, Wildner, Dane, additional, Wörns, Marcus-Alexander, additional, Galle, Peter, additional, and Malek, Nisar, additional

Published
2023
Full Text
View/download PDF

23. Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma

Author

Schmithals, Christian, primary, Köberle, Verena, primary, Korkusuz, Hüdayi, primary, Pleli, Thomas, primary, Kakoschky, Bianca, primary, Augusto, Eduardo Alonso, primary, Ibrahim, Ahmed Atef, primary, Arencibia, Jose M., primary, Vafaizadeh, Vida, primary, Groner, Bernd, primary, Korf, Horst-Werner, primary, Kronenberger, Bernd, primary, Zeuzem, Stefan, primary, Vogl, Thomas J., primary, Waidmann, Oliver, primary, and Piiper, Albrecht, primary

Published
2023
Full Text
View/download PDF

24. Data from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma

Author

Schmithals, Christian, primary, Köberle, Verena, primary, Korkusuz, Hüdayi, primary, Pleli, Thomas, primary, Kakoschky, Bianca, primary, Augusto, Eduardo Alonso, primary, Ibrahim, Ahmed Atef, primary, Arencibia, Jose M., primary, Vafaizadeh, Vida, primary, Groner, Bernd, primary, Korf, Horst-Werner, primary, Kronenberger, Bernd, primary, Zeuzem, Stefan, primary, Vogl, Thomas J., primary, Waidmann, Oliver, primary, and Piiper, Albrecht, primary

Published
2023
Full Text
View/download PDF

26. IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC).

Author

Vogel, Arndt, primary, Waidmann, Oliver, additional, Müller, Tobias, additional, Siegler, Gabriele Margareta, additional, Goetze, Thorsten Oliver, additional, De Toni, Enrico N., additional, Gonzalez-Carmona, Maria A, additional, Hausner, Guido, additional, Geissler, Michael, additional, Fischer von Weikersthal, Ludwig, additional, Kestler, Angelika M. R., additional, Finkelmeier, Fabian, additional, Kleiß, Matthias, additional, Marquardt, Jens U., additional, Teufel, Andreas, additional, Klagges, Jorge, additional, Eickhoff, Regina, additional, Al-Batran, Salah-Eddin, additional, and Saborowski, Anna Lena, additional

Published
2023
Full Text
View/download PDF

27. Atezolizumab plus bevacizumab beyond first-line in hepatocellular carcinoma

Author

Sinner, Friedrich, additional, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Ettrich, Thomas, additional, Sturm, Niklas, additional, Gonzalez-Carmona, MariaA., additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Himmelsbach, Vera, additional, de Toni, EnricoN., additional, Ben-Khaled, Najib, additional, Mohr, Raphael, additional, Fründt, ThorbenWilhelm, additional, Kütting, Fabian, additional, van Bömmel, Florian, additional, Lieb, Sabine, additional, Krug, Sebastian, additional, Bettinger, Dominik, additional, Schultheiß, Michael, additional, Jochheim, Leonie, additional, Best, Jan, additional, Keitel, Verena, additional, Müller, Christian, additional, and Venerito, Marino, additional

Published
2023
Full Text
View/download PDF

29. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms

Author

Voesch Sabrina, Bitzer Michael, Albert Jörg, Bartenstein Peter, Bechstein Wolf, Blödt Susanne, Brunner Thomas, Dombrowski Frank, Evert Matthias, Follmann Markus, La Fougère Christian, Freudenberger Paul, Geier Andreas, Gkika Eleni, Götz Martin, Hammes Elke, Helmberger Thomas, Hoffmann Ralf-Thorsten, Hofmann Wolf-Peter, Huppert Peter, Kautz Achim, Knötgen Gabi, Körber Jürgen, Krug David, Lammert Frank, Lang Hauke, Langer Thomas, Lenz Philipp, Mahnken Andreas, Meining Alexander, Micke Oliver, Nadalin Silvio, Nguyen Huu Phuc, Ockenga Johann, Oldhafer Karl-Jürgen, Paprottka Philipp, Paradies Kerstin, Pereira Philippe, Persigehl Thorsten, Plauth Mathias, Plentz Ruben, Pohl Jürgen, Riemer Jutta, Reimer Peter, Ringwald Johanna, Ritterbusch Ulrike, Roeb Elke, Schellhaas Barbara, Schirmacher Peter, Schmid Irene, Schuler Andreas, von Schweinitz Dietrich, Seehofer Daniel, Sinn Marianne, Stein Alexander, Stengel Andreas, Steubesand Nadine, Stoll Christian, Tannapfel Andrea, Taubert Anne, Trojan Jörg, van Thiel Ingo, Tholen Reina, Vogel Arndt, Vogl Thomas, Vorwerk Hilke, Wacker Frank, Waidmann Oliver, Wedemeyer Heiner, Wege Henning, Wildner Dane, Wittekind Christian, Wörns Marcus-Alexander, Galle Peter, and Malek Nisar

Subjects
Gastroenterology
Published
2022
Full Text
View/download PDF

30. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome

Author

Bitzer, Michael, Groß, Sabrina, Albert, Jörg, Boda-Heggemann, Judit, Brunner, Thomas, Caspari, Reiner, De Toni, Enrico, Dombrowski, Frank, Evert, Matthias, Geier, Andreas, Gkika, Eleni, Götz, Martin, Helmberger, Thomas, Hoffmann, Ralf-Thorsten, Huppert, Peter, Kautz, Achim, Krug, David, Fougère, Christian La, Lang, Hauke, Lenz, Philipp, Lüdde, Tom, Mahnken, Andreas, Nadalin, Silvio, Nguyen, Hoa Huu Phuc, Ockenga, Johann, Oldhafer, Karl, Paprottka, Philipp, Pereira, Philippe, Persigehl, Thorsten, Plentz, Ruben, Pohl, Jürgen, Recken, Heinrich, Reimer, Peter, Riemer, Jutta, Ritterbusch, Ulrike, Roeb, Elke, Rüssel, Jörn, Schellhaas, Barbara, Schirmacher, Peter, Schlitt, Hans Jürgen, Schmid, Irene, Schuler, Andreas, Seehofer, Daniel, Sinn, Marianne, Stengel, Andreas, Stoll, Christoph, Tannapfel, Andrea, Taubert, Anne, Tholen, Reina, Trojan, Jörg, van Thiel, Ingo, Vogel, Arndt, Vogl, Thomas, Wacker, Frank, Waidmann, Oliver, Wedemeyer, Heiner, Wege, Henning, Wildner, Dane, Wörns, Marcus-Alexander, Galle, Peter, and Malek, Nisar

Subjects
Medizin
Published
2023

31. Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B

Author

Fischer, Janett, primary, Long, Shuang, additional, Koukoulioti, Eleni, additional, Müller, Tobias, additional, Fueloep, Balazs, additional, Heyne, Renate, additional, Eslam, Mohammed, additional, George, Jacob, additional, Finkelmeier, Fabian, additional, Waidmann, Oliver, additional, Berg, Thomas, additional, and van Bömmel, Florian, additional

Published
2022
Full Text
View/download PDF

32. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience

Author

Sinner, Friedrich, primary, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Ettrich, Thomas Jens, additional, Sturm, Niklas, additional, Gonzalez-Carmona, Maria A., additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Himmelsbach, Vera, additional, De Toni, Enrico N., additional, Ben Khaled, Najib, additional, Mohr, Raphael, additional, Fründt, Thorben Wilhelm, additional, Kütting, Fabian, additional, Bömmel, Florian van, additional, Lieb, Sabine, additional, Krug, Sebastian, additional, Bettinger, Dominik, additional, Schultheiß, Michael, additional, Jochheim, Leonie S., additional, Best, Jan, additional, Müller, Christian, additional, Keitel, Verena, additional, and Venerito, Marino, additional

Published
2022
Full Text
View/download PDF

34. Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study

Author

Hunyady, Peter, primary, Streller, Lea, additional, Rüther, Darius F, additional, Groba, Sara Reinartz, additional, Bettinger, Dominik, additional, Fitting, Daniel, additional, Hamesch, Karim, additional, Marquardt, Jens U, additional, Mücke, Victoria T, additional, Finkelmeier, Fabian, additional, Sekandarzad, Asieb, additional, Wengenmayer, Tobias, additional, Bounidane, Ayoub, additional, Weiss, Felicitas, additional, Peiffer, Kai-Henrik, additional, Schlevogt, Bernhard, additional, Zeuzem, Stefan, additional, Waidmann, Oliver, additional, Hollenbach, Marcus, additional, Kirstein, Martha M, additional, Kluwe, Johannes, additional, Kütting, Fabian, additional, and Mücke, Marcus M, additional

Published
2022
Full Text
View/download PDF

35. Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study

Author

Hunyady, Peter, primary, Streller, Lea, additional, Ruether, Darius, additional, Groba, Sara Reinartz, additional, Bettinger, Dominik, additional, Fitting, Daniel, additional, Hamesch, Karim, additional, Marquardt, Jens, additional, Mücke, Victoria, additional, Finkelmeier, Fabian, additional, Sekandarzad, Asieb, additional, Wengenmayer, Tobias, additional, Bounidane, Ayoub, additional, Weiss, Felicitas, additional, Peiffer, Kai-Henrick, additional, Schlevogt, Bernhard, additional, Zeuzem, Stefan, additional, Waidmann, Oliver, additional, Hollenbach, Marcus, additional, Kirstein, Martha M, additional, Kluwe, Johannes, additional, Kütting, Fabian, additional, and Mücke, Marcus, additional

Published
2022
Full Text
View/download PDF

36. Survival according to therapy regimen for small intestinal neuroendocrine tumors

Author

Koch, Christine, Bambey, Cornelia, Filmann, Sonja Natalie, Stanke, Marc, Waidmann, Oliver, Husmann, Gabriele, Bojunga, Jörg, Koch, Christine, Bambey, Cornelia, Filmann, Sonja Natalie, Stanke, Marc, Waidmann, Oliver, Husmann, Gabriele, and Bojunga, Jörg

Abstract

Introduction: Scarce data exist for therapy regimens other than somatostatin analogues (SSA) and peptide receptor radiotherapy (PRRT) for siNET. We analyzed real world data for differences in survival according to therapy. Patients and methods: Analysis of 145 patients, diagnosed between 1993 and 2018 at a single institution, divided in treatment groups. Group (gr.) 0: no treatment (n = 10), gr 1: TACE and/or PRRT (n = 26), gr. 2: SSA (n = 32), gr. 3: SSA/PRRT (n = 8), gr. 4: chemotherapy (n = 8), gr. 5: not metastasized (at diagnosis), surgery only (n = 53), gr. 6 = metastasized (at diagnosis), surgery only (n = 10). Results: 45.5% female, median age 60 years (range, 27–84). A total of 125/145 patients with a resection of the primary tumor. For all patients, 1-year OS (%) was 93.8 (95%-CI: 90–98), 3-year OS = 84.3 (CI: 78–90) and 5-year OS = 77.5 (CI: 70–85). For analysis of survival according to therapy, only stage IV patients (baseline) that received treatment were included. Compared with reference gr. 2 (SSA only), HR for OS was 1.49 (p = 0.47) for gr. 1, 0.72 (p = 0.69) for gr. 3, 2.34 (p = 0.19) for gr. 4. The 5 y OS rate of patients whose primary tumor was resected (n = 125) was 73.1%, and without PTR was 33.3% (HR: 4.31; p = 0.003). Individual patients are represented in swimmer plots. Conclusions: For stage IV patients in this analysis (limited by low patient numbers in co. 3/4), multimodal treatment did not significantly improve survival over SSA treatment alone. A resection of primary tumor significantly improves survival.

Published
2022

37. Comparison of short-course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation

Author

Ferstl, Philip, Queck, Alexander David Roger, Bremer, Katharina, Filmann, Sonja Natalie, Weiler, Nina, Welker, Martin-Walter, Waidmann, Oliver, Knabe, Mate, Bechstein, Wolf Otto, Hogardt, Michael, Kempf, Volkhard A. J., Zeuzem, Stefan, Trebicka, Jonel, Friedrich-Rust, Mireen, Walter, Dirk, Ferstl, Philip, Queck, Alexander David Roger, Bremer, Katharina, Filmann, Sonja Natalie, Weiler, Nina, Welker, Martin-Walter, Waidmann, Oliver, Knabe, Mate, Bechstein, Wolf Otto, Hogardt, Michael, Kempf, Volkhard A. J., Zeuzem, Stefan, Trebicka, Jonel, Friedrich-Rust, Mireen, and Walter, Dirk

Abstract

Objectives: Stenosis of the biliary anastomosis predisposes liver graft recipients to bacterial cholangitis. Antibiotic therapy (AT) is performed according to individual clinical judgment, but duration of AT remains unclear. Methods: All liver graft recipients with acute cholangitis according to the Tokyo criteria grade 1 and 2 after endoscopic retrograde cholangiography (ERC) were included. Outcome of patients treated with short AT (<7 days) was compared to long AT (>6 days). Recurrent cholangitis (RC) within 28 days was the primary end point. Results: In total, 30 patients were included with a median of 313 (range 34–9849) days after liver transplantation until first proven cholangitis. Among 62 cases in total, 51/62 (82%) were graded as Tokyo-1 and 11/62 (18%) as Tokyo-2. Overall median duration of AT was 6 days (1–14) with 36 cases (58%) receiving short AT and 26 (42%) receiving long AT. RC was observed in 10 (16%) cases, without significant difference in occurrence of RC in short versus long AT cases. CRP and bilirubin were significantly higher in patients with long AT, while low serum albumin and low platelets were associated with risk of RC. Conclusion: A shorter antibiotic course than 7 days shows good results in selected, ERC-treated patients for post-transplantation biliary strictures.

Published
2022

38. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience

Author

Sinner, Friedrich, Pinter, Matthias, Scheiner, Bernhard, Ettrich, Thomas Jens, Sturm, Niklas, Gonzalez-Carmona, Maria A., Waidmann, Oliver, Finkelmeier, Fabian, Himmelsbach, Vera, De Toni, Enrico N., Ben Khaled, Najib, Mohr, Raphael, Fruendt, Thorben Wilhelm, Kuetting, Fabian, van Boemmel, Florian, Lieb, Sabine, Krug, Sebastian, Bettinger, Dominik, Schultheiss, Michael, Jochheim, Leonie S., Best, Jan, Mueller, Christian, Keitel, Verena, Venerito, Marino, Sinner, Friedrich, Pinter, Matthias, Scheiner, Bernhard, Ettrich, Thomas Jens, Sturm, Niklas, Gonzalez-Carmona, Maria A., Waidmann, Oliver, Finkelmeier, Fabian, Himmelsbach, Vera, De Toni, Enrico N., Ben Khaled, Najib, Mohr, Raphael, Fruendt, Thorben Wilhelm, Kuetting, Fabian, van Boemmel, Florian, Lieb, Sabine, Krug, Sebastian, Bettinger, Dominik, Schultheiss, Michael, Jochheim, Leonie S., Best, Jan, Mueller, Christian, Keitel, Verena, and Venerito, Marino

Abstract

Simple Summary Hepatocellular cancer is the most common type of primary liver cancer. It is the third leading cause of cancer-related deaths worldwide and its incidence is increasing: >1 million new cases per year expected by 2025. Despite advances in treatment in recent years, diagnosis is associated with poor overall survival. Treatment of hepatocellular cancer depends on the patient's general health and fitness, how well the liver is working, the number and size of tumors in the liver, and whether or not the tumor has spread to other neighboring or distant parts of the body. The combination of atezolizumab plus bevacizumab, two intravenously administered antibodies, is the preferred first-line treatment for patients with advanced hepatocellular cancer that has spread from the liver to other neighboring or distant parts of the body. This study investigated how long patients whose hepatocellular cancer continues to grow (progress) despite one or more prior tumor therapies live when they receive atezolizumab plus bevacizumab. These patients, treated with atezolizumab plus bevacizumab at various hospitals in Germany and Austria, lived about 16 months, which is about 5-8 months longer than patients receiving approved drugs. The safety profile was consistent with previous reports. Atezolizumab plus bevacizumab is the standard of care for first-line systemic therapy for advanced hepatocellular carcinoma (aHCC). Data on the efficacy and safety of atezolizumab plus bevacizumab in patients with aHCC who have received prior systemic therapy are not available. Methods: Patients with aHCC who received atezolizumab plus bevacizumab after at least one systemic treatment between December 2018 and March 2022 were retrospectively identified in 13 centers in Germany and Austria. Patient characteristics, tumor response rates, progression-free survival (PFS), overall survival (OS), and adverse events (AE) were analyzed. Results: A total of 50 patients were identified; 41 (82%) were m

Published
2022

39. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers

Author

Himmelsbach, Vera, Pinter, Matthias, Scheiner, Bernhard, Venerito, Marino, Sinner, Friedrich, Zimpel, Carolin, Marquardt, Jens, Trojan, Jörg, Waidmann, Oliver, Finkelmeier, Fabian, Himmelsbach, Vera, Pinter, Matthias, Scheiner, Bernhard, Venerito, Marino, Sinner, Friedrich, Zimpel, Carolin, Marquardt, Jens, Trojan, Jörg, Waidmann, Oliver, and Finkelmeier, Fabian

Abstract

The combination of atezolizumab and bevacizumab (A + B) is the new standard of care for the systemic first-line treatment of hepatocellular carcinoma (HCC). However, up to now there are only few data on the safety and efficacy of A + B in real life. We included patients with advanced HCC treated with A + B as first-line therapy at four cancer centers in Germany and Austria between December 2018 and August 2021. Demographics, overall survival (OS), and adverse events were assessed until 15 September 2021. We included 66 patients. Most patients had compensated cirrhosis (n = 34; 52%), while Child–Pugh class B cirrhosis was observed in 23 patients (35%), and class C cirrhosis in 5 patients (8%). The best responses included a complete response (CR) in 7 patients (11%), a partial response (PR) in 12 patients (18%), stable disease (SD) in 22 patients (33%), and progressive disease in 11 patients (17%). The median progression-free (PFS) survival was 6.5 months, while the median overall survival (OS) was not reached in this cohort (6-month OS: 69%, 12-month OS: 60%, 18-month OS: 58%). Patients with viral hepatitis seemed to have a better prognosis than patients with HCC of non-viral etiology. The real-world PFS and OS were comparable to those of the pivotal IMBRAVE trial, despite including patients with worse liver function in this study. We conclude that A + B is also highly effective in a real-life setting, with manageable toxicity, especially in patients with compensated liver disease. In patients with compromised liver function (Child B and C), the treatment showed low efficacy and, therefore, it should be well considered before administration to these patients.

Published
2022

40. Low platelet count predicts reduced survival in potentially resectable hepatocellular carcinoma

Author

Schrecker, Christopher, Waidmann, Oliver, Youzouri, Hanan el, Trojan, Jörg, Schnitzbauer, Andreas, Bechstein, Wolf Otto, Zeuzem, Stefan, Koch, Christine, Schrecker, Christopher, Waidmann, Oliver, Youzouri, Hanan el, Trojan, Jörg, Schnitzbauer, Andreas, Bechstein, Wolf Otto, Zeuzem, Stefan, and Koch, Christine

Abstract

The prognostic role of platelet count in hepatocellular carcinoma (HCC) remains unclear, and in fact both thrombocytopenia and thrombocytosis are reported as predictors of unfavourable outcomes. This study aimed to clarify the prognostic value of preoperative platelet count in potentially resectable HCC. We retrospectively reviewed 128 patients who underwent hepatic resection for HCC at a tertiary academic centre (2007–2019). Patient data were modelled by regression analysis, and platelet count was treated as a continuous variable. 89 patients had BCLC 0/A tumours and 39 had BCLC B tumours. Platelet count was higher in patients with larger tumours and lower in patients with higher MELD scores, advanced fibrosis, and portal hypertension (p < 0.001 for all listed variables). After adjusting for BCLC stage and tumour diameter, low platelet count associated with reduced overall survival (hazard ratio 1.25 per 50/nL decrease in platelet count, 95% confidence interval (CI) 1.02–1.53, p = 0.034) and increased perioperative mortality (odds ratio 1.96 per 50/nL decrease in platelet count, 95% CI 1.19–3.53, p = 0.014). Overall, low platelet count correlates with increased liver disease severity, inferior survival, and excess perioperative mortality in resectable HCC. These insights might be applied in clinical practice to better select patients for resection.

Published
2022

41. Comparison of short‐course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation

Author

Ferstl, Philip G., primary, Queck, Alexander, additional, Bremer, Katharina, additional, Filmann, Natalie, additional, Weiler, Nina, additional, Welker, Martin‐W., additional, Waidmann, Oliver, additional, Knabe, Mate, additional, Bechstein, Wolf O., additional, Hogardt, Michael, additional, Kempf, Volkhard A. J., additional, Zeuzem, Stefan, additional, Trebicka, Jonel, additional, Friedrich‐Rust, Mireen, additional, and Walter, Dirk, additional

Published
2022
Full Text
View/download PDF

43. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL

Author

Voesch Sabrina, Bitzer Michael, Albert Jörg, Bartenstein Peter, Bechstein Wolf, Blödt Susanne, Brunner Thomas, Dombrowski Frank, Evert Matthias, Follmann Markus, La Fougère Christian, Freudenberger Paul, Geier Andreas, Gkika Eleni, Götz Martin, Hammes Elke, Helmberger Thomas, Hoffmann Ralf-Thorsten, Hofmann Wolf-Peter, Huppert Peter, Kautz Achim, Knötgen Gabi, Körber Jürgen, Krug David, Lammert Frank, Lang Hauke, Langer Thomas, Lenz Philipp, Mahnken Andreas, Meining Alexander, Micke Oliver, Nadalin Silvio, Nguyen Huu Phuc, Ockenga Johann, Oldhafer Karl-Jürgen, Paprottka Philipp, Paradies Kerstin, Pereira Philippe, Persigehl Thorsten, Plauth Mathias, Plentz Ruben, Pohl Jürgen, Riemer Jutta, Reimer Peter, Ringwald Johanna, Ritterbusch Ulrike, Roeb Elke, Schellhaas Barbara, Schirmacher Peter, Schmid Irene, Schuler Andreas, von Schweinitz Dietrich, Seehofer Daniel, Sinn Marianne, Stein Alexander, Stengel Andreas, Steubesand Nadine, Stoll Christian, Tannapfel Andrea, Taubert Anne, Trojan Jörg, van Thiel Ingo, Tholen Reina, Vogel Arndt, Vogl Thomas, Vorwerk Hilke, Wacker Frank, Waidmann Oliver, Wedemeyer Heiner, Wege Henning, Wildner Dane, Wittekind Christian, Wörns Marcus-Alexander, Galle Peter, and Malek Nisar

Subjects
Gastroenterology, Medizin
Abstract

Weitere Nicht-UDE Autoren sind nicht genannt.

Published
2022

44. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers

Author

Himmelsbach, Vera, primary, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Venerito, Marino, additional, Sinner, Friedrich, additional, Zimpel, Carolin, additional, Marquardt, Jens U., additional, Trojan, Jörg, additional, Waidmann, Oliver, additional, and Finkelmeier, Fabian, additional

Published
2022
Full Text
View/download PDF

47. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study

Author

Welland, Sabrina, primary, Leyh, Catherine, additional, Finkelmeier, Fabian, additional, Jefremow, André, additional, Shmanko, Kateryna, additional, Gonzalez-Carmona, Maria A., additional, Kandulski, Arne, additional, Jeliazkova, Petia, additional, Best, Jan, additional, Fründt, Thorben W., additional, Djanani, Angela, additional, Pangerl, Maria, additional, Maieron, Andreas, additional, Greil, Richard, additional, Fricke, Christina, additional, Sookthai, Disorn, additional, Günther, Rainer, additional, Schmiderer, Andreas, additional, Wege, Henning, additional, Venerito, Marino, additional, Ehmer, Ursula, additional, Müller, Martina, additional, Strassburg, Christian P., additional, Weinmann, Arndt, additional, Siebler, Jürgen, additional, Waidmann, Oliver, additional, Lange, Christian M., additional, Saborowski, Anna, additional, and Vogel, Arndt, additional

Published
2022
Full Text
View/download PDF

48. Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study.

Author

Hunyady, Peter, Streller, Lea, Rüther, Darius F, Groba, Sara Reinartz, Bettinger, Dominik, Fitting, Daniel, Hamesch, Karim, Marquardt, Jens U, Mücke, Victoria T, Finkelmeier, Fabian, Sekandarzad, Asieb, Wengenmayer, Tobias, Bounidane, Ayoub, Weiss, Felicitas, Peiffer, Kai-Henrik, Schlevogt, Bernhard, Zeuzem, Stefan, Waidmann, Oliver, Hollenbach, Marcus, and Kirstein, Martha M

Subjects
RESEARCH, HOST-bacteria relationships, INTENSIVE care units, COVID-19, CONFIDENCE intervals, CRITICALLY ill, LOG-rank test, ENDOSCOPIC retrograde cholangiopancreatography, PATIENTS, RETROSPECTIVE studies, TERTIARY care, DRUG resistance, BILE duct diseases, ARTIFICIAL respiration, SURVIVAL analysis (Biometry), CRITICAL care medicine, BILE acids, ODDS ratio, PHENOTYPES
Abstract

Background Secondary sclerosing cholangitis (SSC) is a rare disease with poor prognosis. Cases of SSC have been reported following coronavirus disease 2019 (COVID-SSC). The aim of this study was to compare COVID-SSC to SSC in critically ill patients (SSC-CIP) and to assess factors influencing transplant-free survival. Methods In this retrospective, multicenter study involving 127 patients with SSC from 9 tertiary care centers in Germany, COVID-SSC was compared to SSC-CIP and logistic regression analyses were performed investigating factors impacting transplant-free survival. Results Twenty-four patients had COVID-SSC, 77 patients SSC-CIP, and 26 patients other forms of SSC. COVID-SSC developed after a median of 91 days following COVID-19 diagnosis. All patients had received extensive intensive care treatment (median days of mechanical ventilation, 48). Patients with COVID-SSC and SSC-CIP were comparable in most of the clinical parameters and transplant-free survival was not different from other forms of SSC (P =.443, log-rank test). In the overall cohort, the use of ursodeoxycholic acid (UDCA) (odds ratio [OR], 0.36 [95% confidence interval {CI},.16–.80], P =.013; log-rank P <.001) and high serum albumin levels (OR, 0.40 [95% CI,.17–.96], P =.040) were independently associated with an increased transplant-free survival, while the presence of liver cirrhosis (OR, 2.52 [95% CI, 1.01–6.25], P =.047) was associated with worse outcome. Multidrug-resistant organism (MDRO) colonization or infection did not impact patients' survival. Conclusions COVID-SSC and CIP-SSC share the same clinical phenotype, course of the disease, and risk factors for its development. UDCA may be a promising therapeutic option in SSC, though future prospective trials are needed to confirm our findings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B.

Author

Fischer, Janett, Long, Shuang, Koukoulioti, Eleni, Müller, Tobias, Fueloep, Balazs, Heyne, Renate, Eslam, Mohammed, George, Jacob, Finkelmeier, Fabian, Waidmann, Oliver, Berg, Thomas, and van Bömmel, Florian

Subjects
CHRONIC hepatitis B, HEPATOCELLULAR carcinoma, INTERLEUKIN-1, SINGLE nucleotide polymorphisms, HEPATITIS B virus, HEPATITIS B
Abstract

Interleukin-1 beta (IL-1β) promotes liver disease progression and hepatocarcinogenesis in chronic hepatitis B (CHB). Single nucleotide polymorphisms (SNPs) within the promotor region of the IL-1β gene can affect the progression towards liver cirrhosis and hepatocellular carcinoma (HCC). Aims: We aimed to investigate the association of three common IL-1β SNPs with hepatitis B virus (HBV)-related HCC in Caucasian patients. Method: A Caucasian cohort of 99 patients with HBe antigen (Ag)-positive CHB, 255 patients with HBeAg-negative CHB and 278 inactive carriers (IC) were enrolled. 105 patients were diagnosed with liver cirrhosis, and 64 with HCC and cirrhosis. Genotyping of the IL-1β rs1143623, rs1143627 and rs16944 was performed. Results: The rs1143627 TT and rs16944 CC genotypes were more frequent in patients with HCC compared to patients without liver tumours (48% vs. 33%, p = 0.018 and 47% vs. 31%, p = 0.001, respectively). In multivariate analysis, the rs16944 CC genotype was independently associated with HCC (OR = 6.44 [95% CI 1.50–27.59] p = 0.012). The haplotype, including rs1143623 TT and rs16944 CC, was a risk factor for HCC development (OR = 1.55 [95% CI 1.04–2.32] p = 0.031). Conclusions: We identified an association of common IL-1β SNPs with HBV-related HCC in a Caucasian population. The effect was independent of the phases of chronic HBV infection, which are currently regarded as important HCC risk factors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Mismatch Repair Deficiency, Chemotherapy and Survival for Resectable Gastric Cancer: an Observational Study from the German staR Cohort and a Meta-Analysis

Author

Stolze, Thilo, primary, Franke, Sabine, additional, Haybaeck, Johannes, additional, Moehler, Markus, additional, Grimminger, Peter P., additional, Lang, Hauke, additional, Roth, Wilfried, additional, Gockel, Ines, additional, Kreuser, Nicole, additional, Bläker, Hendrik, additional, Wittekind, Christian, additional, Lordick, Florian, additional, Vieth, Michael, additional, Veits, Lothar, additional, Waidmann, Oliver, additional, Lingohr, Philipp, additional, Peitz, Ulrich, additional, Schildberg, Claus, additional, Kruschewski, Martin, additional, Vassos, Nikolaos, additional, Goni, Elisabetta, additional, Bruns, Christiane J., additional, Ridwelski, Karsten, additional, Wolff, Stefanie, additional, Lippert, Hans, additional, Schumacher, Johannes, additional, Malfertheiner, Peter, additional, and Venerito, Marino, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results